Gary Ingenito Sells 6,152 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating) insider Gary Ingenito sold 6,152 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, June 22nd. The stock was sold at an average price of $6.61, for a total value of $40,664.72. Following the completion of the transaction, the insider now directly owns 22,053 shares in the company, valued at $145,770.33. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

NASDAQ:CPRX traded up $0.12 during mid-day trading on Thursday, hitting $6.69. The company’s stock had a trading volume of 1,285,495 shares, compared to its average volume of 1,139,078. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $4.81 and a fifty-two week high of $8.65. The company has a market capitalization of $687.60 million, a price-to-earnings ratio of 15.64 and a beta of 1.30. The stock has a fifty day moving average of $7.22 and a 200-day moving average of $7.18.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.02). Catalyst Pharmaceuticals had a return on equity of 23.95% and a net margin of 29.31%. The business had revenue of $43.09 million during the quarter, compared to analyst estimates of $43.17 million. During the same period last year, the company earned $0.09 EPS. Sell-side analysts expect that Catalyst Pharmaceuticals, Inc. will post 0.67 EPS for the current year.

A number of research firms have recently issued reports on CPRX. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 20th. Truist Financial restated a “buy” rating and set a $12.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, March 18th. Finally, Piper Sandler boosted their price objective on Catalyst Pharmaceuticals from $8.00 to $8.75 in a research report on Thursday, March 17th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $10.92.

Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 1.7% during the third quarter. Geode Capital Management LLC now owns 1,896,976 shares of the biopharmaceutical company’s stock worth $10,053,000 after buying an additional 32,343 shares in the last quarter. Credit Suisse AG increased its holdings in shares of Catalyst Pharmaceuticals by 10.7% during the third quarter. Credit Suisse AG now owns 71,025 shares of the biopharmaceutical company’s stock worth $376,000 after buying an additional 6,868 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Catalyst Pharmaceuticals by 20.1% during the third quarter. Dimensional Fund Advisors LP now owns 1,753,974 shares of the biopharmaceutical company’s stock worth $9,294,000 after buying an additional 293,033 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Catalyst Pharmaceuticals by 86.8% during the third quarter. Cubist Systematic Strategies LLC now owns 112,195 shares of the biopharmaceutical company’s stock worth $595,000 after buying an additional 52,140 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY increased its holdings in shares of Catalyst Pharmaceuticals by 18.4% during the third quarter. Metropolitan Life Insurance Co NY now owns 26,407 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 4,109 shares in the last quarter. 64.28% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile (Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Recommended Stories

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.